TerminatedNCT06029439
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Researchers are studying NMRA-335140, tracking side effects to assess long-term safety and tolerability in people with depression.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
Researchers are studying NMRA-335140, tracking side effects to assess long-term safety and tolerability in people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Huntsville and 177 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 10, 2023
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 904
- Sponsor
- Neumora Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06029439
- Official title
Show the full official title
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder
Recruitment & locations
TerminatedHuntsville, United States · Phoenix, United States · Bentonville, United States
136 more locations
- Little Rock, United States
- Rogers, United States
- Bellflower, United States
- Cerritos, United States
- Encino, United States
- Garden Grove, United States
- Glendale, United States
- Imperial, United States
- Irvine, United States
- Lafayette, United States
- Long Beach, United States
- Los Angeles, United States
- Newport Beach, United States
- Oceanside, United States
- Orange, United States
- Riverside, United States
- San Diego, United States
- San Francisco, United States
- San Jose, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Temecula, United States
- Torrance, United States
- Colorado Springs, United States
- New Haven, United States
- Norwalk, United States
- Bradenton, United States
- Brandon, United States
- Gainesville, United States
- Hallandale, United States
- Hialeah, United States
- Hollywood, United States
- Jacksonville, United States
- Lauderhill, United States
- Maitland, United States
- Miami, United States
- Miami Beach, United States
- Miami Lakes, United States
- Miami Springs, United States
- Orlando, United States
- Pembroke Pines, United States
- Pompano Beach, United States
- Saint Augustine, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Savannah, United States
- Chicago, United States
- Warrenville, United States
- Marrero, United States
- New Orleans, United States
- Baltimore, United States
- Towson, United States
- Boston, United States
- Methuen, United States
- Springfield, United States
- Watertown, United States
- Bloomfield Township, United States
- Mankato, United States
- Flowood, United States
- Saint Charles, United States
- St Louis, United States
- Las Vegas, United States
- Berlin, United States
- Princeton, United States
- Toms River, United States
- Albuquerque, United States
- Brooklyn, United States
- Buffalo, United States
- Cedarhurst, United States
- Inwood, United States
- New York, United States
- Staten Island, United States
- The Bronx, United States
- Charlotte, United States
- Monroe, United States
- Columbus, United States
- Dayton, United States
- North Canton, United States
- Edmond, United States
- Oklahoma City, United States
- Allentown, United States
- Media, United States
- Philadelphia, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- Wichita Falls, United States
- Bellevue, United States
- Everett, United States
- Curitiba, Brazil
- Botafogo - Rio de Janeiro, Brazil
- Porto Alegre, Brazil
- Santa Cecília, Brazil
- São Bernardo do Campo, Brazil
- São José do Rio Preto, Brazil
- São Paulo, Brazil
- Cherven Bryag, Bulgaria
- Sofia, Bulgaria
- Varosha, Bulgaria
- Kardzhali, Bulgaria
- Pleven, Bulgaria
- Varna, Bulgaria
- Kelowna, Canada
- Hamilton, Canada
- Markham, Canada
- Mississauga, Canada
- Toronto, Canada
- Santiago, Chile
- Antofagasta, Chile
- Pilsen, Czechia
- Prague, Czechia
- Kladno, Czechia
- Helsinki, Finland
- Turku, Finland
- Oulu, Finland
- Clermont-Ferrand, France
- Douai, France
- Montpellier, France
- La Roche-sur-Yon, France
- Poitiers, France
- Berlin, Germany
- Hamburg, Germany
- Suchy Las, Poland
- Bydgoszcz, Poland
- Wroclaw, Poland
- Lublin, Poland
- Białystok, Poland
- Gdansk, Poland
- Lund, Sweden
- Stockholm, Sweden
- Czechia
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are studying NMRA-335140, tracking side effects to assess long-term safety and tolerability in people with depression.
Who is behind this study?
The study sponsor is Neumora Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including NMRA-335140.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS pa...